Priority Review Voucher Extension Scaled Back In New Cures Bill
This article was originally published in The Pink Sheet Daily
Pediatric rare disease program would have been renewed for seven years under previous draft, but now would only have a three-year on life as full committee mark-up begins.
You may also be interested in...
House Commerce Committee members are drafting legislation to make numerous significant changes to the 340B drug discount program, including the definition of eligible patients, new reporting and auditing requirements for providers and drug manufacturers, rules for contract pharmacies – and a new user-fee program for participating health care providers.
Knight Therapeutics says a rare pediatric disease voucher is more valuable than its tropical disease voucher despite the sale price.
Companies’ decision to purchase and redeem BioMarin’s priority review voucher for their PCSK9 inhibitor alirocumab sets the first public benchmark for a voucher’s value and shows the potential advantages to be gained for sponsors in a race to market.